Medical Oncology & Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, 20089, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, 20072, Italy.
Future Oncol. 2024 Mar;20(7):373-380. doi: 10.2217/fon-2023-0952. Epub 2024 Mar 6.
This retrospective study aims to identify a possible predictive role of mutations in non-small-cell lung cancer in response to first-line pembrolizumab, either as monotherapy or combined with chemotherapy. Patients received pembrolizumab alone (n = 213) or associated with chemotherapy (n = 81). A mutation in the gene was detected in 27% of patients. In patients on pembrolizumab alone, median progression-free survival in -mutated cases was longer than in wild-type cases (11.3 vs 4.4 months; p = 0.019), whereas median overall survival did not reach statistical significance (22.1 vs 12.5 months; p = 0.119). Patients receiving chemo-immunotherapy with -positive tumors had a similar progression-free survival (9.7 vs 7.3 months; p = 0.435); overall survival data were immature. This study suggests a correlation between status and response to pembrolizumab.
本回顾性研究旨在确定非小细胞肺癌患者中 基因突变是否可能对一线帕博利珠单抗（单药或联合化疗）治疗有预测作用。患者接受帕博利珠单抗单药治疗（n=213）或联合化疗（n=81）。检测到 基因中有突变的患者占 27%。在接受帕博利珠单抗单药治疗的患者中， 突变阳性病例的无进展生存期长于野生型病例（11.3 个月比 4.4 个月；p=0.019），但总生存期无统计学意义（22.1 个月比 12.5 个月；p=0.119）。接受含 阳性肿瘤的化疗免疫治疗的患者无进展生存期相似（9.7 个月比 7.3 个月；p=0.435）；总生存数据不成熟。本研究提示 状态与帕博利珠单抗治疗反应之间存在相关性。
